CND Life Sciences re-raises from S-Curve to scale skin-biopsy neurology test
What's the deal? CND Life Sciences, a Scottsdale, Arizona-based neurodiagnostics company, has completed a growth financing led by S-Curve PartnersDealroom has a profile for this one. Try Dealroom →, an operator-led healthcare investment firm. Existing CND investors and shareholders also joined the round.
What does CND do? It develops the Syn-One Test, the first commercially available skin biopsy-based lab test designed to detect abnormal alpha-synuclein and other pathological markers. The platform helps clinicians evaluate patients with suspected Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and related synucleinopathies.
By the numbers: Since 2020, more than 4,000 neurologists and other clinicians across the US have used Syn-One to support the diagnostic evaluation of over 60,000 patients.
A quick re-raise: The deal marks a fast follow-on for CND, which is deepening its relationship with S-Curve rather than courting fresh backers. That repeat participation from existing shareholders signals continued confidence in the company's commercial trajectory.
What's the money for? Proceeds will support growth of the Syn-One platform, commercial expansion, product innovation, and strategic partnerships. CND also plans to fold Syn-One into a broader multimodal biomarker capability for diagnosing and characterising neurodegenerative disorders.
Why now? The financing lands amid heightened interest in objective biomarkers, earlier diagnosis, and precision medicine in neurology. "As disease-modifying therapies emerge, objective biomarkers will only become more essential for clinicians, patients, researchers, and pharmaceutical companies," said Daniel Livschutz, founding partner of S-Curve Partners.
What's the endgame? S-Curve wants to help CND evolve "from a category-defining product to a broader platform supporting earlier diagnosis, disease differentiation, and more personalized care," Livschutz said. Chief executive officer Rick Morello framed the deal as validation of "the science behind our scalable neurodiagnostics platform."
The signal: Neurodegenerative diseases remain among the most underdiagnosed and misdiagnosed conditions in medicine. As the field shifts toward multimodal biomarkers and earlier intervention, capital is flowing to diagnostics firms positioned to catch these disorders sooner.
Read more: PR Newswire
Image credit: Generated with Gemini
